18-19 novembre 2022
CONGRESSO ATBV 2022
Filmati dei lavori
I giornata
ABOVE AND BEYOND LDL CHOLESTEROL
Gaetano Maria De Ferrari, Maddalena Lettino
Optimal Use of Statins, Ezetimibe, and Bempedoic Acid in Clinical Practice – Paolo Calabrò
Evolutions of PCSK9 Inhibition – Giuseppe Musumeci
Icosapent ethyl is different than PolyUnsaturated Fatty Acids: Understanding REDUCE IT – Giuseppe Patti
The future is now: Lipoprotein (a) inhibition and more! – Alberico Catapano
SPOTLIGHT SESSION: UPDATES ON ATHEROSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY FROM ESC AND AHA 2022
Claudio Ceconi, Anna Franzone
Late-Breaking Updates from ESC.2022 – Ilaria Cavallari
Late-Breaking Updates from AHA.22 – Felice Gragnano
JOINT ATBV-ACVC SESSION: MANAGEMENT OF ANTITHROMBOTHIC
THERAPY IN CRITICALLY ILL PATIENTS
Ingo Ahrens, Maddalena Lettino
Antithrombothic Strategies in Patients with Mechanical Circulatory Support – Christophe Vendenbriele
Atrial Fibrillation in Critically Ill Patients – Kurt Huber
SPOTLIGHT SESSION: ESTABLISHED AND EMERGING PARENTERAL
ANTIPLATELET AGENTS
Alberto Menozzi, Raffaele Piccolo
Cangrelor and Glycoprotein IIb/IIIa Inhibitors: Different Drugs, Different Roles – Leonardo De Luca
Future Pre-Hospital Strategies: Selatogrel and RUC-4 – Felice Gragnano
THE WORST CHALLENGES REVEAL THE BEST CLINICIANS: TRANSLATING EVIDENCE AND EXPERIENCE TO THE INDIVIDUAL PATIENT
Walter Ageno, Gaetano Maria De Ferrari
Challenge #1: Intracranial Hemorrage with a Mechanical Mitral Valve – Marco Mennuni; The Expert Responds: Stefano De Servi
Challenge #3: Unplanned Abdominal Surgery After High Risk PCI – Claudio Montalto; The Expert Responds: Stefano Savonitto
Challenge #4: New Onset Atrial Fibrillation in a Patient with Severe Anemia and Recent Cancer – Letizia Riva; The Expert Responds: Claudio Cuccia
SPECIAL SESSION WITH THE PRINCIPAL INVESTIGATORS INSIGHTS FROM THE INSIDE: FROM STUDY DESIGN TO EVIDENCE INTERPRETATION
Sergio Leonardi, Williem J.M. Dewilde
RE-DUAL PCI: A Tale of Two Doses and Drugs – Christopher Cannon, interviewed by Andrea Rubboli
AUGUSTUS, finally a factorial design – Renato Lopes, interviewed by Sergio Leonardi
Last but not least: ENTRUST-AF PCI – Pascal Vranckx, interviewed by Marco Valgimigli
II giornata
EVOLVING ANTITHROMBOTIC STRATEGIES IN PATIENTS WITH ACUTE AND CHRONIC CORONARY SYNDROME: TOWARD PERSONALIZED MEDICINE?
Claudio Fresco, Luigi Oltrona Visconti
Is Guided Antiplatelet Therapy Ready for Prime Time? – Davide Capodanno
Indication and Timing of P2Y12 Inhibitors Monotherapy After ACS – Leonardo Bolognese
Vascular Dose of Rivaroxaban: From Evidence to Pratcice – Marco Ferlini
Bridgining Antithrombothic Strategies in Patients with Coronary Stent Requiring Surgery – Giuseppe Musumeci
BURNING HEART
Giuseppe Patti, Aldo Pietro Maggioni
Repurposing Colchicine: From Inflammation to Acute and Chronic Coronary Syndrome Use – Massimo Imazio
Inflammatory Citokines, Now an Actionable Target – Pasquale Perrone Filardi
State-of-the-Art Lecture: Targeting Inflammation in Cardiovascular Diseases – Raffaele De Caterina
Joint Session with ESC WG on Thrombosis-LATE-BREAKING INNOVATIONS IN ANTITHROMBOTHIC THERAPY
Andrea Rubboli, Bianca Rocca
Novel Targets in the Coagulation Pathway – Diana Gorog
Factor XIa Inhibition: a Novel Bleeding Minimize Strategy – Gianluca Campo
OPTIMAL ANTITHROMBOTHIC THERAPY IN PATIENTS UNDERGOING STRUCTURAL HEART PROCEDURES
Alaide Chieffo, Ferdinando Varbella
Transcathether Aortic Valve Replacement – Anna Franzone
Left Atrial Appendage Occlusion and Exclusion – Francesco Costa
Mitral Valve Procedures – Gabriele Crimi
Special Lecture: The Physician-Patient Alliance – Claudio Cuccia, interviewed by Sergio Leonardi
SPOTLIGHT SESSION: REPURPOSING ANTI-DIABETIC DRUGS: PRESENT AND FUTURE USE OF SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS AND GLP-1 RECEPTOR AGONISTS
Stefano De Servi, Sergio Leonardi
GLP-1 RA in Patients with Obesity – Angelo Avogaro
SGLT2i in Patients with Aterothrombosis, with and without heart failure – Stephen Wiviott